M. Lynn Crismon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
M. Lynn Crismon has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Nick C. Patel
Division of Pharmacy Practice, College of Pharmacy, Department of Psychiatry, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA
4 shared publicationsPatricia L. Canales
College of Pharmacy, The University of Texas (UT), Austin State Hospital, Austin, TX, USA
2 shared publicationsAaron P. Gibson
University of Texas at Austin and Austin State Hospital, Office of Medical Director for Behavioral Health (Texas Department of State Health Services), and Seton Shoal Creek Hospital, Texas 78712-0125, USA
1 shared publicationAlexander L. Miller
University of Texas Health Science Center at San Antonio, San Antonio, Texas
1 shared publication- Alexander L. Miller
Department of Psychiatry, University of Texas Health Science Center, San Antonio, San Antonio, USA
1 shared publication Allen Frances
Department of Psychiatry, Duke University, Durham, NC
1 shared publication
Latest Publications
- 1 January 2009
- Vol. 88 (1) , 71-100
The use of psychotropic medication for children in foster care.
The use of psychotropic medication for foster children is in itself not unique; however, these children are of particular interest because of the stress associated with their life situations. A thorough assessment of the child and family should occur before beginning these medications, and in general, they should only be used in the presence of a Diagnostic and Statistical Manual, 4th edition, diagnosis of a mental disorder. Parents and caregivers need to be aware of principles of use, potential side effects, and monitoring parameters.
- 1 January 2009
- Vol. 88 (1) , 71-100
The use of psychotropic medication for children in foster care.
The use of psychotropic medication for foster children is in itself not unique; however, these children are of particular interest because of the stress associated with their life situations. A thorough assessment of the child and family should occur before beginning these medications, and in general, they should only be used in the presence of a Diagnostic and Statistical Manual, 4th edition, diagnosis of a mental disorder. Parents and caregivers need to be aware of principles of use, potential side effects, and monitoring parameters.
- 1 March 2007
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 22 (2) , 101-105
Effectiveness and tolerability of aripiprazole in child and adolescent inpatients: a retrospective evaluation
The objective of this study was to evaluate the effectiveness and tolerability of aripiprazole use in child and adolescent psychiatric inpatients. This was a naturalistic, retrospective evaluation of the discharged patients treated with aripiprazole on the child and adolescent unit at the Austin State Hospital. To be included, patients had to be Z=−5.179, P<0.001). Fifty-one percent of the youth had a clinical global impression of severity of illness score that was much improved or very much improved (clinical global impression of improvement score of 1 or 2). Significant reduction in clinical global impression of severity of illness scores suggests a decline in the symptom severity for patients treated with aripiprazole. On the basis of the reported adverse events and side effects, aripiprazole was generally well tolerated. Randomized controlled trials of aripiprazole in childhood mental disorders are warranted.
- 1 March 2007
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 22 (2) , 101-105
Effectiveness and tolerability of aripiprazole in child and adolescent inpatients: a retrospective evaluation
The objective of this study was to evaluate the effectiveness and tolerability of aripiprazole use in child and adolescent psychiatric inpatients. This was a naturalistic, retrospective evaluation of the discharged patients treated with aripiprazole on the child and adolescent unit at the Austin State Hospital. To be included, patients had to be Z=−5.179, P<0.001). Fifty-one percent of the youth had a clinical global impression of severity of illness score that was much improved or very much improved (clinical global impression of improvement score of 1 or 2). Significant reduction in clinical global impression of severity of illness scores suggests a decline in the symptom severity for patients treated with aripiprazole. On the basis of the reported adverse events and side effects, aripiprazole was generally well tolerated. Randomized controlled trials of aripiprazole in childhood mental disorders are warranted.
- 1 September 2006
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 40 (9) , 1649-1650
Clinical Psychopharmacology: Advances and Challenges from 1965 to 2006
- 1 September 2006
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 40 (9) , 1649-1650
Clinical Psychopharmacology: Advances and Challenges from 1965 to 2006
- 1 September 2005
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 25 (9) , 1242-1247
Drug Adherence: Effects of Decreased Visit Frequency on Adherence to Clozapine Therapy
Objective. To study the effects of visit frequency on drug‐adherence parameters subsequent to the change in the United States Food and Drug Administration (FDA)‐mandated monitoring of white blood cell counts from weekly to every 2 weeks (biweekly) after 6 months of clozapine therapy.Methods. Paid prescription claims records for clozapine from September 1, 1995–August 31, 2001, were extracted Texas Medicaid Vendor Drug Program database. Two groups of subjects were identified: subjects treated before and those treated after the FDA labeling change in monitoring frequency, which occurred on April 1, 1998. Prescription claims records for each subject were assessed for 365 days after the initial 6 months of therapy. Adherence measures included persistence, medication possession ratio (MPR), and time taking clozapine.Results. Subjects receiving weekly hematologic monitoring had significantly higher rates of persistence (0.79 ± 0.35 vs 0.70 ± 0.38, pConclusion. Significant effects of visit frequency on adherence to clozapine therapy were noted. For patients inadequately adherent to therapy, an increase in visit frequency may improve adherence, and based on these results, the extra visits do not need to be with a physician or have any specific purpose other than contact with a provider.
- 1 September 2005
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 25 (9) , 1242-1247
Drug Adherence: Effects of Decreased Visit Frequency on Adherence to Clozapine Therapy
Objective. To study the effects of visit frequency on drug‐adherence parameters subsequent to the change in the United States Food and Drug Administration (FDA)‐mandated monitoring of white blood cell counts from weekly to every 2 weeks (biweekly) after 6 months of clozapine therapy.Methods. Paid prescription claims records for clozapine from September 1, 1995–August 31, 2001, were extracted Texas Medicaid Vendor Drug Program database. Two groups of subjects were identified: subjects treated before and those treated after the FDA labeling change in monitoring frequency, which occurred on April 1, 1998. Prescription claims records for each subject were assessed for 365 days after the initial 6 months of therapy. Adherence measures included persistence, medication possession ratio (MPR), and time taking clozapine.Results. Subjects receiving weekly hematologic monitoring had significantly higher rates of persistence (0.79 ± 0.35 vs 0.70 ± 0.38, pConclusion. Significant effects of visit frequency on adherence to clozapine therapy were noted. For patients inadequately adherent to therapy, an increase in visit frequency may improve adherence, and based on these results, the extra visits do not need to be with a physician or have any specific purpose other than contact with a provider.
- 1 July 2005
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 25 (7) , 909-917
Assessment of Adherence Measures with Different Stimulants Among Children and Adolescents
Study Objective. To examine adherence measures with different stimulants in children and adolescents.Design. Retrospective analysis.Data Source. Texas Medicaid prescription claims database.Patients. A total of 9549 patients aged 5–18 years with attention‐deficit—hyperactivity disorder.Measurements and Main Results. Paid prescription claims for newly started stimulants during the 2001–2002 school year were extracted from a database; 28,344 prescriptions (9549 patients) were available for analysis. Adherence was evaluated based on the drug therapy prescribed (i.e., mixed amphetamine salts, immediate‐release methylphenidate, and extended‐release methylphenidate—OROS [oral‐osmotic formulation]) and the age and sex of the patient. Adherence measures were persistence and medication possession ratio (MPR). Persistence was higher for extended‐release methylphenidate—OROS (0.50 ± 0.33) than for mixed amphetamine salts (0.42 ± 0.29) or immediate‐release methylphenidate (0.37 ± 0.26; pConclusion. Adherence measures in our study were low. Although they were significantly better for extended‐release methylphenidate—OROS than the other stimulants, the clinical significance of these differences are unclear. Further research should be conducted regarding pharmaceutical products, administration methods, and clinical interventions that may enhance adherence.
- 1 July 2005
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 25 (7) , 909-917
Assessment of Adherence Measures with Different Stimulants Among Children and Adolescents
Study Objective. To examine adherence measures with different stimulants in children and adolescents.Design. Retrospective analysis.Data Source. Texas Medicaid prescription claims database.Patients. A total of 9549 patients aged 5–18 years with attention‐deficit—hyperactivity disorder.Measurements and Main Results. Paid prescription claims for newly started stimulants during the 2001–2002 school year were extracted from a database; 28,344 prescriptions (9549 patients) were available for analysis. Adherence was evaluated based on the drug therapy prescribed (i.e., mixed amphetamine salts, immediate‐release methylphenidate, and extended‐release methylphenidate—OROS [oral‐osmotic formulation]) and the age and sex of the patient. Adherence measures were persistence and medication possession ratio (MPR). Persistence was higher for extended‐release methylphenidate—OROS (0.50 ± 0.33) than for mixed amphetamine salts (0.42 ± 0.29) or immediate‐release methylphenidate (0.37 ± 0.26; pConclusion. Adherence measures in our study were low. Although they were significantly better for extended‐release methylphenidate—OROS than the other stimulants, the clinical significance of these differences are unclear. Further research should be conducted regarding pharmaceutical products, administration methods, and clinical interventions that may enhance adherence.
- 1 July 2004
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 24 (7) , 824-830
A Retrospective Analysis of the Short‐Term Effects of Olanzapine and Quetiapine on Weight and Body Mass Index in Children and Adolescents
Study Objective. To evaluate changes in short‐term weight and body mass index (BMI) in children and adolescents receiving olanzapine or quetiapine. Design. Retrospective study. Setting. Austin State Hospital, Austin, Texas. Patients. One hundred three patients younger than 18 years who were admitted to the hospital and treated with olanzapine (50 patients) or quetiapine (53) for at least 2 weeks between October 1, 1997, and October 31, 2001. Intervention. Treatment with at least 2 weeks of olanzapine or quetiapine. Measurements and Main Results. Mean ± SD daily doses of olanzapine and quetiapine were 13.9 ± 7.3 and 510.9 ± 250.3 mg, respectively. Weight and height were measured at baseline and 14 or more days after baseline. Body mass index (in kg/m 2 ) was calculated using serial measurements of weight and height, and change in BMI was determined. The olanzapine group gained an average of 3.8 kg, the quetiapine group 0.03 kg. In the olanzapine group, BMI increased by an average of 1.3 kg/m 2 ; in the quetiapine group, BMI decreased by 0.2 kg/m 2 . After controlling for baseline differences, significant between‐group differences in weight and BMI change were noted. Change in BMI correlated significantly with baseline BMI in quetiapine‐treated girls. Conclusion. Patients taking olanzapine had greater increases in weight and BMI than those taking quetiapine. Further studies are necessary to determine the relative risk, magnitude, and time course of antipsychotic‐induced weight gain in this patient population.
- 1 July 2004
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 24 (7) , 824-830
A Retrospective Analysis of the Short‐Term Effects of Olanzapine and Quetiapine on Weight and Body Mass Index in Children and Adolescents
Study Objective. To evaluate changes in short‐term weight and body mass index (BMI) in children and adolescents receiving olanzapine or quetiapine. Design. Retrospective study. Setting. Austin State Hospital, Austin, Texas. Patients. One hundred three patients younger than 18 years who were admitted to the hospital and treated with olanzapine (50 patients) or quetiapine (53) for at least 2 weeks between October 1, 1997, and October 31, 2001. Intervention. Treatment with at least 2 weeks of olanzapine or quetiapine. Measurements and Main Results. Mean ± SD daily doses of olanzapine and quetiapine were 13.9 ± 7.3 and 510.9 ± 250.3 mg, respectively. Weight and height were measured at baseline and 14 or more days after baseline. Body mass index (in kg/m 2 ) was calculated using serial measurements of weight and height, and change in BMI was determined. The olanzapine group gained an average of 3.8 kg, the quetiapine group 0.03 kg. In the olanzapine group, BMI increased by an average of 1.3 kg/m 2 ; in the quetiapine group, BMI decreased by 0.2 kg/m 2 . After controlling for baseline differences, significant between‐group differences in weight and BMI change were noted. Change in BMI correlated significantly with baseline BMI in quetiapine‐treated girls. Conclusion. Patients taking olanzapine had greater increases in weight and BMI than those taking quetiapine. Further studies are necessary to determine the relative risk, magnitude, and time course of antipsychotic‐induced weight gain in this patient population.
- 1 December 2003
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 183 (06) , 498-506
Quantitative analysis of sponsorship bias in economic studies of antidepressants
Background: Concern is widespread about potential sponsorship influence on research, especially in pharmacoeconomic studies. Quantitative analysis of possible bias in such studies is limited. Aims: To determine whether there is an association between sponsorship and quantitative outcomes in pharmacoeconomic studies of antidepressants. Method: Using all identifiable articles with original comparative quantitative cost or cost-effectiveness outcomes for antidepressants, we performed contingency table analyses of study sponsorship and design v. study outcome. Results: Studies sponsored by selective serotonin reuptake inhibitor (SSR1) manufacturers favoured SSRIs over tricyclic antidepressants more than non-industry-sponsored studies. Studies sponsored by manufacturers of newer antidepressants favoured these drugs more than did non-industry-sponsored studies. Among industry-sponsored studies, modelling studies favoured the sponsor's drug more than did administrative studies. Industry-sponsored modelling studies were more favourable to industry than were non-industry-sponsored ones. Conclusions: Pharmacoeconomic studies of antidepressants reveal clear associations of study sponsorship with quantitative outcome.
- 1 December 2003
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 183 (06) , 498-506
Quantitative analysis of sponsorship bias in economic studies of antidepressants
Background: Concern is widespread about potential sponsorship influence on research, especially in pharmacoeconomic studies. Quantitative analysis of possible bias in such studies is limited. Aims: To determine whether there is an association between sponsorship and quantitative outcomes in pharmacoeconomic studies of antidepressants. Method: Using all identifiable articles with original comparative quantitative cost or cost-effectiveness outcomes for antidepressants, we performed contingency table analyses of study sponsorship and design v. study outcome. Results: Studies sponsored by selective serotonin reuptake inhibitor (SSR1) manufacturers favoured SSRIs over tricyclic antidepressants more than non-industry-sponsored studies. Studies sponsored by manufacturers of newer antidepressants favoured these drugs more than did non-industry-sponsored studies. Among industry-sponsored studies, modelling studies favoured the sponsor's drug more than did administrative studies. Industry-sponsored modelling studies were more favourable to industry than were non-industry-sponsored ones. Conclusions: Pharmacoeconomic studies of antidepressants reveal clear associations of study sponsorship with quantitative outcome.
- Open Access
- 15 July 2003
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 60 (14) , 1459-1467
Evaluation of a schizophrenia medication algorithm in a state hospital
Provider’s practice behaviors before and after physician and staff training in the use of a schizophrenia medication algorithm and the effects of education on physician adherence to the algorithm were evaluated. Medical records of 30 patients admitted between September 1 and November 30, 1999, and 30 patients admitted from September 1 to November 30, 2000, with an admitting and discharge diagnosis of schizophrenia and a minimum length of stay of 14 days were randomly selected and analyzed. Clinical data, including prescribed psychotropic medications and dosages, documentation of target symptoms and severity, adverse drug effects, appropriate clinical ratings, patient's response to treatment, and reason for medication change, were collected and compared with the recommendations in the schizophrenia medication algorithm. Efforts to implement the schizophrenia algorithm included staff education and uniform documentation. Progress notes were evaluated before and after training. After physician and staff training, only 5 of 359 progress notes were written using the recommended documentation form. The number of progress notes containing no documentation of symptoms decreased from 66 to 41, and those documenting three to five target symptoms increased from 74 to 140. Documentation of physician assessment of the presence or absence of adverse effects and their severity decreased from 35.2% to 18.7% and from 22.3% to 17.0%, respectively. Physicians increased the documentation of their clinical global impressions from 12.1% to 20.3%. The recording of medication changes increased twofold, but the difference was not significant. Physician and staff education alone did not significantly alter providers’ practice behavior. Inadequate and inconsistent documentation of clinical outcomes made it difficult to assess physician adherence to the treatment algorithm.
- 15 July 2003
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 60 (14) , 1459-1467
Open AccessEvaluation of a schizophrenia medication algorithm in a state hospital
Provider’s practice behaviors before and after physician and staff training in the use of a schizophrenia medication algorithm and the effects of education on physician adherence to the algorithm were evaluated. Medical records of 30 patients admitted between September 1 and November 30, 1999, and 30 patients admitted from September 1 to November 30, 2000, with an admitting and discharge diagnosis of schizophrenia and a minimum length of stay of 14 days were randomly selected and analyzed. Clinical data, including prescribed psychotropic medications and dosages, documentation of target symptoms and severity, adverse drug effects, appropriate clinical ratings, patient's response to treatment, and reason for medication change, were collected and compared with the recommendations in the schizophrenia medication algorithm. Efforts to implement the schizophrenia algorithm included staff education and uniform documentation. Progress notes were evaluated before and after training. After physician and staff training, only 5 of 359 progress notes were written using the recommended documentation form. The number of progress notes containing no documentation of symptoms decreased from 66 to 41, and those documenting three to five target symptoms increased from 74 to 140. Documentation of physician assessment of the presence or absence of adverse effects and their severity decreased from 35.2% to 18.7% and from 22.3% to 17.0%, respectively. Physicians increased the documentation of their clinical global impressions from 12.1% to 20.3%. The recording of medication changes increased twofold, but the difference was not significant. Physician and staff education alone did not significantly alter providers’ practice behavior. Inadequate and inconsistent documentation of clinical outcomes made it difficult to assess physician adherence to the treatment algorithm.
- 1 February 2003
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 23 (2) , 222-230
A Survey of Herbal Use in Children with Attention‐Deficit—Hyperactivity Disorder or Depression
Objective . To examine whether herbal medicines were given to children or adolescents receiving care for attention‐deficit‐hyperactivity disorder or depression. Methods . Between October 2000 and July 2001, a 23‐item questionnaire was administered in five community mental health centers in Texas. Parents or primary caregivers of children who received a psychiatric assessment were sought for participation. One hundred seventeen caregivers completed a questionnaire. The main outcome measure was primary caregivers' self‐report of the use of herbal therapy in their children. Results . The lifetime prevalence of herbal therapy in patients was 20% (23 patients). Eighteen patients (15%) had taken herbal medicines during the past year. Recommendations from a friend or relative resulted in the administration of herbal medicines by 61% of 23 caregivers. Herbal medicines were given most frequently for a behavioral condition, with ginkgo biloba, echinacea, and St. John's wort most prevalent. Almost 83% of caregivers gave herbal medicines alone, whereas 13% gave herbal medicines with prescription drugs. Most caregivers (78%) supervised the administration of herbal therapy in their children; the children's psychiatrists (70%), pediatricians (56%), or pharmacists (74%) typically were not aware of the use. Conclusions . Most caregivers supervised herbal therapy in their children, without communication with a health professional. A need exists for better communication between health professionals and caregivers regarding the use of herbal therapy.
- 1 February 2003
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 23 (2) , 222-230
A Survey of Herbal Use in Children with Attention‐Deficit—Hyperactivity Disorder or Depression
Objective . To examine whether herbal medicines were given to children or adolescents receiving care for attention‐deficit‐hyperactivity disorder or depression. Methods . Between October 2000 and July 2001, a 23‐item questionnaire was administered in five community mental health centers in Texas. Parents or primary caregivers of children who received a psychiatric assessment were sought for participation. One hundred seventeen caregivers completed a questionnaire. The main outcome measure was primary caregivers' self‐report of the use of herbal therapy in their children. Results . The lifetime prevalence of herbal therapy in patients was 20% (23 patients). Eighteen patients (15%) had taken herbal medicines during the past year. Recommendations from a friend or relative resulted in the administration of herbal medicines by 61% of 23 caregivers. Herbal medicines were given most frequently for a behavioral condition, with ginkgo biloba, echinacea, and St. John's wort most prevalent. Almost 83% of caregivers gave herbal medicines alone, whereas 13% gave herbal medicines with prescription drugs. Most caregivers (78%) supervised the administration of herbal therapy in their children; the children's psychiatrists (70%), pediatricians (56%), or pharmacists (74%) typically were not aware of the use. Conclusions . Most caregivers supervised herbal therapy in their children, without communication with a health professional. A need exists for better communication between health professionals and caregivers regarding the use of herbal therapy.
- 1 July 2002
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 22 (7) , 905-914
Secretin Treatment for Autistic Disorder: A Critical Analysis
We assessed evidence of the effects of secretin on behavior in individuals with autistic disorder. Articles were obtained through a MEDLINE search of the English‐language literature from January 1966–November 2001; all investigations and case reports on the topic were included. Press releases obtained from the World Wide Web also were included. Secretin, a gastrointestinal hormone, is suggested to improve autistic symptoms, particularly social function and communication. Two formulations, porcine and synthetic human secretin, were evaluated in humans. A small body of literature and popular belief in autistic disorder communities supported the agent's efficacy. A number of controlled clinical trials did not show improvement in autistic symptoms with secretin compared with placebo, possibly indicating no role for the drug in autistic disorder.
- 1 July 2002
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 22 (7) , 905-914
Secretin Treatment for Autistic Disorder: A Critical Analysis
We assessed evidence of the effects of secretin on behavior in individuals with autistic disorder. Articles were obtained through a MEDLINE search of the English‐language literature from January 1966–November 2001; all investigations and case reports on the topic were included. Press releases obtained from the World Wide Web also were included. Secretin, a gastrointestinal hormone, is suggested to improve autistic symptoms, particularly social function and communication. Two formulations, porcine and synthetic human secretin, were evaluated in humans. A small body of literature and popular belief in autistic disorder communities supported the agent's efficacy. A number of controlled clinical trials did not show improvement in autistic symptoms with secretin compared with placebo, possibly indicating no role for the drug in autistic disorder.